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Abstract
Routine thromboprophylaxis (TP) in newly-diagnosed multiple myeloma (NDMM) patients comprises either aspirin for 
standard risk patients or low molecular weight heparin for high risk patients. Studies using DOACs in cancer patients include 
few with myeloma. The aim of this feasibility clinical trial was to establish the foundations for creating a multicentre trial and 
identify any safety concerns with apixaban. Patient perspectives were sought. NDMM patients were stratified according to 
VTE risk and randomised to either standard TP or apixaban 2.5 mg BD and reviewed every 3 weeks throughout their chemo-
therapy. Two focus groups were carried out on 2 occasions at King’s College Hospital and Guy’s Hospital, London. Each 
lasted an hour, were recorded, transcribed and themes explored using NVivo 11. Ten patients were recruited, 2 considered 
high risk and received apixaban and 8 standard risk; 4 randomised to aspirin and 4 to apixaban. Five patients and 2 carers 
participated in the focus groups. There were no major bleeding or VTE events. Patients were not aware of the thrombotic risk 
associated with cancer. There is a lack of both written and verbal information on this topic. Myeloma patients were happy to 
be included in more than one trial simultaneously. Our study provides information on the difficulties facing physicians and 
patients on obtaining evidence of the safety of DOACs in the context of myeloma. Despite patients being happy to co-recruit 
into thromboprophylaxis trials along with chemotherapy trials this is not current practice.
EudraCT Number: 2015-002668-18
Keywords Multiple myeloma · DOACs · Apixaban · Venous thromboembolism · Thromboprophylaxis · Aspirin · 
Enoxaparin · Clinical trial
Highlights
• The aims of this feasibility clinical trial were to establish 
the foundations for creating a multicentre trial
• Patient perspectives were sought on co-recruitment to 
two trials (one chemotherapy and one thromboprophy-
lactic trial) and views on thrombotic risk in cancer
• This study suggests that apixaban should be fully evalu-
ated for use in those with NDMM as thromboprophylaxis 
as there were no major bleeding or VTE events
• Patients were unaware of thrombotic risk associated with 
cancer
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• Future myeloma thromboprophylactic trial recruitment 
could be improved if conducted in conjunction with 
chemotherapy trials, with a method of including patients 
already in receipt of an anticoagulant or antiplatelet 
agent; patients are willing to be co-recruited.
Introduction
Myeloma patients have an increased risk of venous thrombo-
embolism (VTE) [1] due to patient-, disease- and treatment-
related factors [2]. The British Society of Haematology 
(BSH) suggest a risk assessment model for the prevention 
of VTE in myeloma patients treated with thalidomide or 
lenalidomide. This was stipulated in 2008 prior to the new 
generation of myeloma treatments that are available [3]. It 
suggests that for myeloma patients not receiving thalido-
mide or lenalidomide, thromboprophylaxis (TP) should be 
considered on a case-by-case basis, leaving ambiguity about 
thrombotic risk associated with other and newer agents. The 
UK Myeloma XI study demonstrated a VTE rate of 11.8% 
despite adequate TP according to current guidelines high-
lighting scope for improvement [4].
The evidence for the use of DOACs as TP in the can-
cer cohort is expanding. The Apixaban to Prevent Venous 
Thromboembolism in Patients with Cancer trial [5], aimed 
to assess the safety of apixaban in the context of VTE pre-
vention in cancer. This placebo-controlled, double-blind 
clinical trial assessed the efficacy and safety of apixaban 
(2.5 mg BD) for VTE prevention in ambulatory cancer 
patients. The Khorana score was used to identify those with 
cancer at increased risk of VTE. VTE occurred in 12/288 
(4.2%) patients randomised to apixaban compared with 
28/275 (10.2%) patients randomised to placebo. Bleeding 
occurred in 10 patients (3.5%) randomised to apixaban and 
5 (1.8%) to placebo. This trial included 15 myeloma patients. 
It concluded that apixaban is effective at reducing VTE rates 
in those with cancer. The CASSINI trial, using rivaroxaban 
10 mg in a high-risk cancer cohort, found that during the 
intervention period there was a reduction in VTE in those 
receiving rivaroxaban (2.6% vs. 6.4%) [6]. These trials were 
largely conducted in cancer patients who would not usually 
receive ambulatory TP, unlike the myeloma cohort where the 
thrombotic risk is thought to be higher. The Khorana score 
is not used in myeloma patients.
NDMM patients often enter chemotherapy clinical tri-
als so there is a need to understand patients’ thoughts and 
willingness to be enrolled into 2 trials simultaneously; one 
for chemotherapy and another addressing TP. The benefit 
of co-recruitment would allow the thrombotic risk of newer 
chemotherapy agents to be identified as they are being tri-
alled so efficacy and thrombotic risk can be considered 
simultaneously avoiding subsequent clinical equipoise.
The PELICAN study highlighted that cancer patients are 
not aware of their thrombotic risk [7], despite it being the 
second highest cause of mortality in this cohort [8].
The aims of this feasibility clinical trial were twofold: (i) 
to assess the safety of apixaban as thromboprophylaxis in 
NDMM patients and to establish the feasibility of a multi-
centre trial and (ii) to establish cancer patients’ awareness 
of thrombosis risk, determine attitudes to being enrolled to 
multiple trials simultaneously and to explore patients’ views 
and experience of TP.
Patients and methods
King’s College Hospital NHS Foundation Trust is one of 
the largest teaching hospitals in the UK and includes 2 main 
sites; King’s College Hospital and Princess Royal Univer-
sity Hospital (PRUH). We conducted a randomised, open 
label phase IV feasibility clinical trial comparing the safety 
and efficacy of apixaban 2.5 mg twice a day with the stand-
ard thromboprophylactic agents (Fig. 1); enoxaparin 40 mg 
administered as a subcutaneous injection daily if classified 
as high risk of VTE, and aspirin 75 mg orally daily if con-
sidered standard risk of VTE according to the Palumbo risk 
assessment model [3]. NDMM patients were referred by the 
myeloma team, who performed the VTE risk stratification. 
Eligible patients were given a patient information sheet and 
New diagnosis of MM
Inial treatment decided
Risk assessment of VTE 
(based on Brish Society of 
Haematology Guidelines)
Aspirin 75mg 
or
Apixaban 2.5mg bd
Monitoring of VTE and bleeding at clinic follow-up visits 
Thromboprophylaxis
disconnued
Enoxaparin 40mg od
or
Apixaban 2.5mg bd
Standard 
risk
High risk
Paent in remission
Fig. 1  Trial protocol
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consent was obtained from those recruited. Block randomi-
sation was conducted following risk stratification. Patients 
were followed up for 6-months or until in remission.
Primary end points were bleeding requiring cessation of 
prophylactic therapy or an objectively diagnosed VTE.
Patients could withdraw from the study at any time for 
any reason. The investigator also had the right to withdraw 
patients from the study.
Inclusion criteria included NDMM patients requir-
ing chemotherapy, age > 18 years and able to give written 
informed consent. Exclusion criteria included pregnancy or 
breastfeeding, established use of an anticoagulant or anti-
platelet, contraindications to active substances or excipients 
being used and concomitant systemic treatment with strong 
inhibitors of both CYP3A4 and P-gp, and HIV protease 
inhibitors.
TP commenced on the same day as chemotherapy. Bleed-
ing symptoms were recorded according to ISTH guidelines 
[9]. Patients were reviewed 1 week after starting TP to check 
adherence and assess for bleeding and VTE symptoms. 
The next visit was 3 weeks into treatment, with ongoing 
3-weekly reviews coinciding with chemotherapy visits.
An electronic case report form was created and validated 
by the database provider (KCL CTU). This system was regu-
latory compliant (GCP, 21CRF11, EC Clinical Trial Direc-
tive). Source data was entered by the lead researcher (ZS).
Focus groups
Two focus groups (FG) were conducted by the research team 
(ZS and JPP). The first was performed with self-selecting 
patients and carers who form a cancer panel in South Lon-
don. They were asked about participation in trials, thoughts 
on the TIMM trial and knowledge, at time of diagnosis, of 
symptoms and risk of VTE. The second was performed with 
those who had participated in the TiMM trial itself to gain 
feedback about their experiences of the trial and co-recruit-
ment to 2 trials simultaneously. All participants were pro-
vided with information leaflets in advance of the meetings 
and consent forms signed. All discussions were recorded, 
transcribed and analysed using NVivo 11 software. Frame-
work analysis was used to identify predominant themes 
which included:
(1) Knowledge of thrombotic risk
(2) Concern surrounding VTE
(3) Thoughts on the TiMM trial protocol, including views 
on co-recruitment
(4) Formulation of thromboprophylactic medication
This protocol and related documents were submitted and 
approved by the London Central Research Ethics Committee 
(15/LO/131), and the Medicines and Healthcare Products 
Regulatory Agency (40945/0003/001-0001).
Results
The TiMM trial recruited from April 2016 until April 2017. 
Twenty-nine NDMM patients were assessed for eligibil-
ity. Eighteen patients did not meet the eligibility criteria, 
predominantly due to concomitant use of antiplatelets or 
anticoagulants (n = 11). Four patients were excluded as the 
CARDAMON chemotherapy trial withdrew authorisation 
of concurrent supportive trial participation. Ten of 11 eli-
gible patients consented to the TiMM trial with 1 declining 
consent. The baseline characteristics are outlined in Table 1. 
Figure 2 shows assignment and outcome of patients. Three 
were withdrawn from the aspirin arm, and 1 from the apixa-
ban arm.
Efficacy
No VTE events occurred. There were 2 superficial VTE, 
with no extension into the deep veins, diagnosed using 
duplex ultrasonography during the course of the trial. Both 
events were associated with the use of a peripheral cannula 
for chemotherapy administration. One occurred on apixaban 
and one on aspirin; both patients were considered standard 
risk of VTE.
Safety
Adverse events (AEs) included 3 bleeding events; 2 in the 
aspirin arm and 1 in the apixaban arm (classified as high 
VTE risk). All reported bleeding was clinically relevant 
non-major bleeding. Other AEs were considered minor and 
unrelated to the agents under investigation.
Focus group results
Table 2 outlines the characteristics of those who participated.
Knowledge of thrombotic risk
Knowledge surrounding VTE risk came from sources other 
than medical professionals, including family with personal 
experience of VTE. No panellist remembered a discussion 
about their VTE risk or symptoms to be vigilant of. None 
were given written information about this risk and struggled 
to find information on this topic.
I looked it up afterwards and I couldn’t find that……
So I don’t think it’s greatly publicised. [FG0101].
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It was widely acknowledged that at the time of receiving a 
diagnosis of cancer they were overwhelmed, and it may have 
been discussed but they volume of information received was 
so great that they may have forgotten.
Well, if it was, it certainly didn’t register anywhere in 
my brain and then I would have forgotten what was 
said. [FG0104].
Those who had taken part in the TiMM study were clear 
about their risk of VTE as it formed a large discussion with 
the TiMM trial team, at the time of consent.
Concern surrounding VTE
Most felt so many changes occurred due to their cancer 
diagnosis that they wanted doctors to take a paternalistic 
approach to their treatment. They therefore do not remember 
feeling worried or concerned about developing a VTE.
You know the people you are consulting know a lot 
more about it than you do. [FG0101].
FG0101 expressed this thought initially but after develop-
ing a VTE, was more concerned about the risks associated 
with it which may have been related to an increase in her 
knowledge after the event.
Experiences of the TiMM trial
Recruitment to the TiMM trial was viewed positively. One 
patient who was high risk of VTE and would have required 
injections was randomised to receiving oral apixaban. He 
viewed this favourably as he was already self-injecting insu-
lin was relieved to avoid further injections.
Patients approved of TiMM visits coinciding with chemo-
therapy appointments, so no additional time or travel was 
required.
Table 1  Baseline characteristics of TiMM study patients
Category Characteristic Aspirin Apixaban Total
n = 4 n = 6 n = 10
Gender Male sex, n (%) 2 (50) 3 (50) 5 (50)
VTE Risk Standard 4 (100) 4 (67) 8 (80)
High 0 (0) 2 (33) 2 (20)
Mean age, years (SD)
65.0 (8.6) 61.0 (10.5) 63.3 (8.6)
Ethnicity, n (%)
Black 2 (20) 2 (20)
White 4 (100) 4 (80) 8 (80)
Weight kg-n (%) < 70 1 (25) 1 (17) 2 (20)
70 to ≤ 90 2 (50) 3 (50) 5 (50)
> 90 1 (25) 2 (33) 3 (30)
Creatinine clearance, mL/min ≥ 80, n (%) 2 (50) 4 (67) 6 (60)
50 to < 80, n (%) 2 (50) 2 (33) 4 (40
Previous VTE (DVT/PE) 0 (0)
Smoking status
Never smoker 3 (75) 6 (100) 1 [10]
Ex-smoker 1 (25) 0 (0) 9 (90)
Myeloma treatment regimen, n (%)
Velcade/thalidomide/dexamethasone (VTD) 1 (25) 0 (0) 1 [10]
Carfilzomib/cyclophosphamide/dexamethasone (CCD) 2 (50) 5 (83) 7 (70)
Velcade/Melphalan/Prenisolone (VMP) 4 (100) 6 (100) 2 (20)
Multiple myeloma classification, n (%)
Stage 1 2 (50) 3 (50) 5 (50)
Stage 2 1 (25) 3 (50) 4 (40)
Stage 3 1 (25) 0 (0) 1 [10]
VTE risk factors, n (%)
Obesity (BMI > 30) 1 (25) 3 (50) 4 (40)
Recent surgery (< 6 weeks) 0 (0) 1 (17) 1 [10]
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A positive of trial enrolment includes access to unli-
censed medications. Amongst participants there was a 
perception that trial medications were associated with 
improved outcomes.
…would prefer to be treated with the newer drug - 
because they want to be protected. [FG0103].
By partaking in a trial, something positive could be 
achieved from a cancer diagnosis and the more trials they 
could help with, the more useful they felt.
It makes you feel good about yourself. [FG0102].
FG2 viewed their experiences of co-recruitment posi-
tively. The predominant concern about co-recruitment 
to trials in both FGs related to communication between 
teams.
Team A has been… they’ve taken several samples 
and later on in the day, team B comes along to take 
more samples……what happened to all the tubes 
you took this morning? Why can’t you co-ordinate? 
[FG0103].
The main concern patients have is related to their diag-
nosis of cancer. All other aspects, including VTE risk, are 
considered peripheral. If involved in more than one trial, 
their predominant concern would be related to the trial deal-
ing directly with their diagnosis of cancer.
Formulation of thromboprophylaxis medication
It was considered easier to omit an oral medication rather 
than an injectable so adherence may be improved with an 
injectable preparation. Taking tablets is considered a rou-
tine and common part of daily life. FG0103 suggested some 
patients struggling to physically inject themselves may ben-
efit from an oral alternative.
Fig. 2  Assignment of patients 
and outcomes 11 paents eligible
High Risk
n=2 randomised
Apixaban (n=2)
1 withdrawn aer 
baseline following MI
1 completed 
chemotherapy 
following visit 7
LMWH (n=0)
Standard risk
n=8 randomised
Apixaban (n=4)
1 withdrawn following 
visit 2 (cephalic vein 
thrombus)
2 completed 
chemotherapy 
following visit 7
1 completed 
chemotherapy 
following visit 9
Aspirin (n=4)
1 withdrawn following 
visit 1 (Fast AF)
1 withdrawn following 
visit 4 (PR bleed)
1 withdrawn following 
visit 6 (progression of 
myeloma)
1 completed 
chemotherapy at visit 
7 (cephalic vein 
thrombus) 
1 did not consent
(high risk)
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Efficacy was the primary concern for patients rather than 
side effects or frequency of administration. They felt taking 
medications was a process that they had to go through as part 
of their overall treatment.
Discussion
This feasibility clinical trial reports no safety or efficacy 
issues related to the use of apixaban as evidenced by no 
increase in VTE events or bleeding associated with apixaban 
use. The findings suggest patients will consent to a support-
ive clinical trial evaluating thromboprophylaxis whilst being 
treated for myeloma.
Although we did not reach our recruitment target, recruit-
ment to the TiMM trial was good. Patients were motivated to 
take part; 10 of a possible 11 consented to the trial. The main 
issue with recruitment stemmed from the eligibility crite-
ria. Eleven patients referred for eligibility assessment were 
on an alternative anticoagulant or anti-platelet agent which 
precluded them from the TiMM trial. When considering the 
design of future studies, this needs to be carefully considered 
and approaches which allow the inclusion of these patients 
would be beneficial.
Seven patients were co-recruited to TiMM and the CAR-
DAMON study and no patient declined co-recruitment. 
However, due to regulatory approvals, 4 patients who would 
have been candidates for the TiMM study were not eligible 
due to already being enrolled into another study. To improve 
recruitment, our experience suggests future TP trials should 
form a supportive arm of chemotherapy trials. This would 
enable new chemotherapy drugs to be trialled alongside 
thromboprophylaxis, as would be offered in routine clinical 
practice, with the disadvantage of an added confounding 
factor.
This trial suggests apixaban and aspirin may not be suffi-
cient to prevent cannula-associated superficial thrombophle-
bitis. Given that two occurred in a relatively small cohort, 
when chemotherapy combinations include intravenously-
administered drugs, consideration needs to be given to the 
risk of thrombosis associated with an intravenous line and 
irritant chemotherapy and whether this should feature in a 
risk assessment is uncertain. Furthermore, it is unknown 
whether the advent of cannula-associated phlebitis influ-
ences subsequent VTE risk. The management of cannula-
associated thrombophlebitis lacks consensus and warrants 
further research. The optimal duration of thromboprophy-
laxis remains uncertain.
Patients with cancer first and foremost see themselves as 
cancer patients. Their primary concerns are receiving treat-
ment for this and everything else, including VTE preven-
tion is secondary. This has been echoed in the PELICAN 
study [7]. Future VTE trials would ideally be conducted in 
conjunction with chemotherapy treatment. There is a lack 
of research on the VTE risk associated with the new thera-
peutic agents undergoing trials. For example, it is unclear 
if carfilzomib confers the same protection against VTE as 
other proteasome inhibitors [10]. These questions must be 
Table 2  Baseline characteristics of focus group patients
VTE venous thromboembolism, TP thromboprophylaxis, N/A not applicable, AF atrial fibrillation
Code Age (years) Sex (M/F) Carer/patient? Underlying malig-
nancy
VTE TP Participated 
in the TiMM 
trial?
Focus group 1
 FG0101 69 F Patient Breast Cancer Incidental PE during 
chemotherapy 
-treated with 
LMWH
N/A N
 FG0102 71 M Patient Leukaemia N/A N/A N
 FG0103 72 F Carer Husband with pros-
tate cancer
N/A N/A N
 FG0104 66 F Patient Colorectal cancer N/A Now has AF on 
warfarin
N
Focus group 2-both patients had been co-recruited to TiMM and a chemotherapy trial
 FG0201 63 M Patient Myeloma No Apixaban (high VTE 
risk)
Y
 FG0202 60 F Carer (Wife) of 
FG0201
N/A N/A N/A N/A
 FG0203 54 F Patient Myeloma Yes-cannula associ-
ated thrombus on 
trial
Aspirin (low VTE 
risk)
Y
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answered in the context of large, randomised controlled clin-
ical trials, in conjunction with a thromboprophylaxis arm.
The efficacy and side effects of TP were the considered 
more important to patients than whether it was delivered 
orally or subcutaneously. This is supported by other work 
which indicates that the primary concern of cancer patients 
with regards to thromboprophylaxis is an agent that will 
cause the least interference with their cancer treatment, 
regardless of preparation [11].
Patients were unaware of their risk of VTE at the time of 
cancer diagnosis. This is likely related to being overwhelmed 
at diagnosis with information about their malignancy and 
treatment. Given that this is the second commonest cause of 
mortality in this cohort [8], it is important this risk is reiter-
ated at each appointment.
Limitations
It is undoubtedly a limitation that no high-risk patients 
were randomised to low molecular weight hepari (LMWH) 
as both were randomised to apixaban. Lower recruitment 
than expected impacted on the ability to assess VTE rates. 
Relaxing the exclusion criteria of future studies could be 
considered with regards to pre-existing anticoagulation or 
antiplatelet therapy.
Both focus groups had small numbers of patients and 
carers in attendance and although this allowed for a more 
in-depth discussion of topics, it may have been prudent to 
carry out more focus groups to increase numbers. The first 
focus group consisted of cancer patients on a cancer panel, 
rather than myeloma patients. They may also represent a 
self-selecting group of patients as they are likely to be highly 
motivated individuals by the nature of their presence on such 
a panel.
Conclusion
This trial highlights the issues with recruiting NDMM to 
large randomised DOAC thromboprophylaxis trials and 
suggests solutions. Patients are preferentially recruited to 
chemotherapy trials which do not allow co-recruitment. 
Patients support co-recruitment to trials, or an alternative is 
to create a thromboprophylaxis sub-study within myeloma 
chemotherapy trials.
Patients often have comorbidities requiring the use of 
antiplatelets or anticoagulants, if patients are already on 
these agents, there needs to be a mechanism in trial designs 
by which they can be included in TP trials. VTE is still 
poorly understood by myeloma patients and more needs to 
be done to address this.
Acknowledgements This paper presents independent research 
funded by the National Institute for Health Research (NIHR) under 
its Research for Patient Benefit (RfPB) Programme (Grant Refer-
ence Number PB-PG-0614-33101). The views expressed are those of 
the author(s) and not necessarily those of the NHS, the NIHR or the 
Department of Health.
Author contributions All authors designed the research and reviewed 
the manuscript for submission. ZS, JPP and RA performed the research. 
ZS, JPP and VC analysed the data. ZS wrote the paper.
Compliance with ethical standards 
Conflict of interest JC has received honoraria from Bayer Healthcare. 
JPP has received investigator-initiated research funding from Bayer 
Healthcare. RB has received research funding from Servier and Pfizer 
and has been on the advisory board for Gilead, Novartis and Pfizer. LR 
has received speaker fees and a travel grant from Bayer PLC. RA has 
received investigator-initiated research funding from Bayer Healthcare 
and Covidien and honoraria from Bayer Healthcare. Boehringer-Ingel-
heim, Pfizer and Sanofi.
Data availability Further data generated by the study is available via 
request to the corresponding author.
Open Access This article is distributed under the terms of the Creative 
Commons Attribution 4.0 International License (http://creativecom-
mons.org/licenses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.  
References
 1. Srkalovic G, Cameron MG, Rybicki L, Deitcher SR, Kattke-
Marchant K, Hussein MA (2004) Monoclonal gammopathy of 
undetermined significance and multiple myeloma are associated 
with an increased incidence of venothromboembolic disease. Can-
cer 101(3):558–566
 2. Fotiou D, Gerotziafas G, Kastritis E, Dimopoulos MA, Terpos E 
(2016) A review of the venous thrombotic issues associated with 
multiple myeloma. Expert Rev Hematol 9(7):695–706
 3. Palumbo A, Rajkumar SV, Dimopoulos M, Richardson PG, San 
Miguel J, Barlogie B et al (2008) Prevention of thalidomide-
and lenalidomide-associated thrombosis in myeloma. Leukemia 
22(2):414–423
 4. Bradbury CA, Jenner MW, Striha A, Cook G, Pawlyn C, Jones JR 
et al (2017) Thrombotic events in patients with myeloma treated 
with immunomodulatory drugs: results of the myeloma XI study. 
Blood J 130:553
 5. Carrier M, Abou-Nassar K, Mallick R, Tagalakis V, Shivakumar 
S, Schattner A et al (2019) Apixaban to prevent venous thrombo-
embolism in patients with cancer. N Engl J Med 380(8):711–719
 6. Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun 
T et al (2019) Rivaroxaban for thromboprophylaxis in high-risk 
ambulatory patients with cancer. N Engl J Med 380(8):720–728
 7. Noble S, Prout H, Nelson A (2015) Patients’ Experiences of LIv-
ing with CANcer-associated thrombosis: the PELICAN study. 
Patient Prefer Adherence 24(9):337–345
 8. Khorana AA (2010) Venous thromboembolism and prognosis in 
cancer. Thromb Res 125(6):490–493
 Z. Sayar et al.
1 3
 9. Rodeghiero F, Tosetto A, Abshire T, Arnold D, Coller B, James P 
et al (2010) ISTH/SSC bleeding assessment tool: a standardized 
questionnaire and a proposal for a new bleeding score for inherited 
bleeding disorders. J Thromb Haemost 8(9):2063–2065
 10. Zangari M, Fink L, Zhan F, Tricot G (2011) Low venous thrombo-
embolic risk with bortezomib in multiple myeloma and potential 
protective effect with thalidomide/lenalidomide-based therapy: 
review of data from phase 3 trials and studies of novel combina-
tion regimens. Clin Lymphoma Myeloma Leuk 11(2):228–236
 11. Noble S, Matzdorff A, Maraveyas A, Holm MV, Pisa G (2015) 
Assessing patients’ anticoagulation preferences for the treatment 
of cancer-associated thrombosis using conjoint methodology. 
Haematologica 100(11):1486–1492
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
